Mirum Pharmaceuticals Inc. (MIRM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Mirum Pharmaceuticals Inc... (MIRM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

43.33

-0.67 (-1.52%)

At close: Jan 14, 2025, 3:59 PM

43.32

-0.02%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	41
Market Cap	2.08B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.08
PE Ratio (ttm)	-20.83
Forward PE	n/a
Analyst	Buy

Ask	46.92
Volume	773,537
Avg. Volume (20D)	376,100
Open	44.87
Previous Close	44.00
Day's Range	43.20 - 45.10
52-Week Range	23.14 - 48.89
Beta	undefined

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 18, 2019

Employees 311

Stock Exchange NASDAQ

Ticker Symbol MIRM

Website https://www.mirumpharma.com

Analyst Forecast

According to 10 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 45.40% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Mirum Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $86.85M, reflecting a 24.87% YoY growth and earnings per share of -0.34, making a -48.48% decrease YoY.

Why Price Moved

7 months ago · Source

+27.31%

Mirum Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

10 months ago · Source

+1.44%

Mirum Pharmaceuticals shares are trading higher after the company announced that the FDA approved LIVMARLI oral solution for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $45 to $58.

News

1 day ago · zacks.com

Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Mirum Pharmaceuticals (MIRM) could be a great choice. It is one of the several stocks that passed through our "...

2 days ago · businesswire.com

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates.

5 days ago · businesswire.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

1 week ago · seekingalpha.com

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)

1 week ago · businesswire.com

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference.

3 weeks ago · seekingalpha.com

Mirum Pharma: Buy At Dips For Volixibat Potential

Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 yea...

1 month ago · zacks.com

Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

1 month ago · zacks.com

Mirum Shares Surge More Than 90% in 6 Months: Here's Why

MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.

2 months ago · seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief E...

2 months ago · zacks.com

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024.

2 months ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.

2 months ago · businesswire.com

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

2 months ago · businesswire.com

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.

2 months ago · zacks.com

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · businesswire.com

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .